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D50 (Gy) 
10-
20  
20-
30  
30-
40  
40-
50  
50-
60  
>60 
Unknown (no 
effect) 
CONV1 10.3 20.7 13.8 6.9 3.4 10.3 31.0 
CONV2 10.0 25.0 25.0 5.0 10.0 10.0 15.0 
SABR 15.2 27.3 12.1 12.1 9.1 9.1 15.2 
ΔHUmax 
(HU) 
10-
20 
20-
30 
30-
40 
40-
50 
50-
60 
>60 Unknown 
CONV1 13.8 13.8 13.8 13.8 0 13.8 31.0 
CONV2 10.0 35.0 15.0 5.0 10.0 10.0 15.0 
SABR 15.2 27.3 12.1 12.1 9.1 9.1 15.2 
Table 1 
 
 
 
Conclusions 
Baseline CT characteristics allow to identify patient-specific 
and regional differences in sensitivity for radiation-induced 
lung damage. This may be used for further treatment 
individualisation. 
This project has received funding from the European Union's 
Seventh Framework Programme under grant agreement no 
601826' (REQUITE). 
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Purpose/Objective: As urinary symptoms tend to recur 
throughout follow-up, conventional method of analysis using 
cumulative peak event and time-to-event may not be optimal 
to uncover the dosimetric-symptom correlates. We assessed 
the bladder dosimetry and urinary symptom correlates using 
longitudinally-defined endpoints and using recurrent event 
models which are contrasted to the conventional analysis 
methods. 
Materials and Methods: In this study, 754 dose-surface 
information and their corresponding specific urinary 
symptoms (dysuria (D), haematuria (H), incontinence (I) and 
frequency (F)) from a cohort of patients who received 
prostate radiotherapy in the RADAR TROG 03.04 trial were 
analysed. The dosimetric-symptom correlates were analysed 
using; 1) conventional methods (cumulative incidence(peak) 
and time-to-event(Cox) analysis), 2) longitudinally-defined 
endpoint (mean symptoms), 3) recurrent event models using 
the Andersen-Gill extension of the Cox regression model for 
counting process (AG) & generalised estimating equation 
(GEE) models. Dosimetric-symptom correlates were 
contrasted for the different analytic methods. 
Results: For dysuria and haematuria, stronger relationships 
were found to the dose indices using peak and Cox models 
compared to mean symptom, AG and GEE models. Despite 
the different strength of relationship, dose-surface of the 
bladder receiving higher than 65 Gy (S65) and S70 
consistently show strong relationship to dysuria. S60 to S65 
are the most significant for Hpeak , HGEE, HCox and Hmean. None 
of the dosimetric indices satisfy the proportional hazard 
assumption for HAG. For urinary incontinence and frequency, 
stronger relationships for dosimetric indices were found for 
AG, GEE and to lesser extent mean score model while both 
peak and Cox models do not result in significant or show 
trend towards significance. S35 to S40 were found to be the 
most significant for FGEE, Fmean and FAG while S20 to S25 for IAG 
and Imean. 
Conclusions: The use of peak or time-to-event model alone is 
not optimal in assessing dose-volume correlates for certain 
urinary symptoms endpoints. Dosimetric-symptom correlates 
analysis should be supplemented by longitudinally-defined 
endpoints and/or using recurrent event models to account for 
multiple events per patient.  
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Purpose/Objective: To assess clinical and dosimetric factors 
affecting acute urinary toxicities on a large cohort of patients 
treated with external beam radiotherapy (RT) for prostate 
cancer with radical intent. 
Materials and Methods: The final dataset of a prospective 
multicentre study was considered. It included 542 patients 
treated with conventionally (74-80 Gy at 1.8-2 Gy/fr) or 
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moderately hypofractionated RT (65-75.2 Gy at 2.2-2.7 
Gy/fr) in 5 fractions per week.  
Relevant clinical factors were collected for each patient: T 
stage, concomitant morbidities and drugs, androgen 
deprivation (AD), previous surgery, smoking, alcohol, age and 
BMI. Urinary symptoms were self-reported by each patient 
through the International Prostate Symptom Score (IPSS) 
before and after RT; based on previous results, absolute 
(cm2) weekly dose-surface histograms (DSHw) were chosen as 
dosimetry descriptors. 
A multivariate logistic regression (MVR) was performed for 
two endpoints: 1) the onset of moderate-severe urinary 
toxicities at RT end (IPSSend≥15) for a subgroup of patients 
with none/mild symptoms before RT (IPSSbefore<15); 2) the 
worsening of urinary symptoms after RT described by an IPSS 
increase of at least 10 points after RT (DIPSS≥10). 
The choice of relevant factors to be included in the MVR had 
been previously carried out through an in silico methodology 
combining a bootstrap resampling, a backward feature 
selection based on minimization of residuals and a basket and 
network analysis of bootstrapped models. Features with the 
greatest percentage of occurrences (OCC) in the 
bootstrapped models were included in the MVR. A dedicated 
software for data mining (KNIME) was used. 
Results: IPSS scores before and after RT were available for 
429 patients. 
97 out of 385 patients (25%) with none/mild symptoms before 
RT showed IPSSend≥15; while DIPSS≥10 was found in 85/429 
(20%) patients. Results of variable selection and MVR are 
reported in Figure and Table: models with six (AUC=0.70) and 
five variables (AUC=0.66) were considered for the IPSSend≥15 
(1) and DIPSS≥10 (2) endpoints, respectively. 
The most robustly predictive clinical variables were: IPSS 
score before RT (OR=1.17, OCC=92%) in model 1); and AD 
(OR=0.63, OCC=78% and OR=0.49, OCC=72%) and the use of 
anti-hypertensives (OR=2.12, OCC=79% and OR=1.72, 
OCC=40%) present in both models as protective and risk 
factor, respectively. A dosimetric variable was also recovered 
as a risk factor in both models: DSHw at 12.5 Gy (OR=1.02, 
OCC=57%) and DSHw at 8 Gy (OR=1.01, OCC=46%) for 1) and 
2), respectively. 
 
 
 
 
Conclusions: Correlations between clinical/dosimetric 
parameters and the onset or worsening of urinary symptoms 
were studied. 
The role of pre-treatment urinary symptoms was confirmed 
as a risk factor. The medium-high weekly doses and the use 
of anti-hypertensives were found as risk predictors, while AD 
was protective in both analyses. 
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Purpose/Objective: The dose delivered to organs at risk 
differs between patients due to differences in their personal 
anatomies. Such differences may correlate with variations in 
toxicity. For several acute gastrointestinal toxicity endpoints 
we constructed average dose difference maps on the rectal 
surface between the groups of patients with and without 
event. The significance of dose differences was tested. 
Materials and Methods: RTOG (grade ≥1, ≥2) toxicity 
endpoints derived from identical questionnaires were 
available for prostate cancer patients treated to 78Gy in 39 
fractions within two prospective trials, one using 3D-CRT and 
bony set-up correction (n=215), the other using image-guided 
(IG) IMRT with gold markers and reduced PTV margins 
(n=260). Two mappings of the treatment planning dose 
distribution on the delineated rectum surface were defined 
using regular intervals along the central rectum axis. The 
first (rectum) mapping intersects the rectum surface with 
planes perpendicular to this axis, and places the axis origin at 
the half-height of the delineated prostate. The second (anus) 
mapping uses horizontal intersection planes, and places the 
origin at the lowest delineated contour. Dose maps were 
constructed and averaged over patients with and without 
each endpoint, and dose difference maps were generated. 
Significance was tested by normalizing the dose difference to 
the local standard deviation, and calculating p values for the 
maximum normalized difference based on a permutation 
method. Contours were drawn around regions with p<0.05. 
Results: Tighter margins and increased conformity led to 
smaller high dose regions on the anal and rectal surface for 
IG-IMRT patients (Fig. 1a-d), and to lower grade ≥2 GI toxicity 
(29% vs. 49% for 3D-CRT). Significantly higher (p<0.05) local 
dose was found for 3D-CRT patients with proctitis, mucus 
loss, and stool frequency ≥6 in the anus mapping, and for 
